Abstract
Cell cycle progression and cell division are driven by the sequential activation of a group of serine-threonine kinases called cyclin-dependent kinases (Cdks). Multiple Cdks control the cell cycle in mammals and have been long considered essential for normal proliferation, development and homeostasis. The importance of the Cdk-cyclin complexes in cell proliferation is underscored by the fact that deregulation of the Cdk activity is found in virtually the whole spectrum of human tumors. Advances in the cell cycle proteins in the last 25 years, since the discovery of cyclins, have been discussed and have shed even more light on this essential life sustaining process. Recent information from different models for the various cyclins and Cdks have made some of the generally accepted concepts of cell cycle regulation to be revised and new and exciting questions to be investigated. There is also increasing evidence that suggests that Cdks such as Cdc2 are also commonly targeted by viral proteins, which modulate host cell cycle machinery to benefit viral survival or replication. This review, describes some of the most recent and important US patents related to cell cycle regulation and those on viral proteins involved in cell cycle modulation particularly the G2/M phase transition and cancer therapy.
Keywords: Cell cycle regulation, cyclin dependent kinases, cyclins, cell cycle modulation, viral proteins, G2/M phase
Recent Patents on Biotechnology
Title: Recent Patents on Cell Cycle Regulatory Proteins
Volume: 3 Issue: 1
Author(s): Julius L. C. Chulu and Hung J. Liu
Affiliation:
Keywords: Cell cycle regulation, cyclin dependent kinases, cyclins, cell cycle modulation, viral proteins, G2/M phase
Abstract: Cell cycle progression and cell division are driven by the sequential activation of a group of serine-threonine kinases called cyclin-dependent kinases (Cdks). Multiple Cdks control the cell cycle in mammals and have been long considered essential for normal proliferation, development and homeostasis. The importance of the Cdk-cyclin complexes in cell proliferation is underscored by the fact that deregulation of the Cdk activity is found in virtually the whole spectrum of human tumors. Advances in the cell cycle proteins in the last 25 years, since the discovery of cyclins, have been discussed and have shed even more light on this essential life sustaining process. Recent information from different models for the various cyclins and Cdks have made some of the generally accepted concepts of cell cycle regulation to be revised and new and exciting questions to be investigated. There is also increasing evidence that suggests that Cdks such as Cdc2 are also commonly targeted by viral proteins, which modulate host cell cycle machinery to benefit viral survival or replication. This review, describes some of the most recent and important US patents related to cell cycle regulation and those on viral proteins involved in cell cycle modulation particularly the G2/M phase transition and cancer therapy.
Export Options
About this article
Cite this article as:
Chulu L. C. Julius and Liu J. Hung, Recent Patents on Cell Cycle Regulatory Proteins, Recent Patents on Biotechnology 2009; 3(1) . https://dx.doi.org/10.2174/187220809787172614
DOI https://dx.doi.org/10.2174/187220809787172614 |
Print ISSN 1872-2083 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-4012 |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility Of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Tumoral Drug Metabolism: Perspectives and Therapeutic Implications
Current Drug Metabolism Melatonin Regulates Angiogenic and Inflammatory Proteins in MDA-MB-231 Cell Line and in Co-culture with Cancer-associated Fibroblasts
Anti-Cancer Agents in Medicinal Chemistry Heterocyclic Drug-polymer Conjugates for Cancer Targeted Drug Delivery
Anti-Cancer Agents in Medicinal Chemistry The Metaboloepigenetic Dimension of Cancer Stem Cells: Evaluating the Market Potential for New Metabostemness-Targeting Oncology Drugs
Current Pharmaceutical Design Folate Targeted Solid Lipid Nanoparticles of Simvastatin for Enhanced Cytotoxic Effects of Doxorubicin in Chronic Myeloid Leukemia
Current Nanoscience Cancer Stem Cells Switch on Tumor Neovascularization
Current Molecular Medicine Applications of 211At and 223Ra in Targeted Alpha-Particle Radiotherapy
Current Radiopharmaceuticals Mesothelioma - Update on Management
Current Respiratory Medicine Reviews Progress in Topical siRNA Delivery Approaches for Skin Disorders
Current Pharmaceutical Design Neuronal Semaphorins Regulate a Primary Immune Response
Current Neurovascular Research Proton Ion-Microbeam Elemental Analysis for Inhaled Particle-Induced Pulmonary Diseases: Application for Diagnosis and Assessment of Progression
Current Medicinal Chemistry Intercalation of Erlotinib and Pemetrexed in the Treatment of Non-Small Cell Lung Cancer
Current Drug Targets Disulfiram's Anticancer Activity: Evidence and Mechanisms
Anti-Cancer Agents in Medicinal Chemistry HGF Airway Over-expression Leads to Enhanced Pulmonary Vascularization without Induction of VEGF
Current Angiogenesis (Discontinued) Potential Applications of FDG-PET/CT in COPD: A Review of the Literature
Current Molecular Imaging (Discontinued) Adenoviral Vector-Mediated Gene Transfer for Human Gene Therapy
Current Gene Therapy Targeting the Most Upstream Site of Wnt Signaling Pathway Provides a Strategic Advantage for Therapy in Colorectal Cancer
Current Drug Targets Sch-66336 (Sarasar®) and Other Benzocycloheptapyridyl Farnesyl Protein Transferase Inhibitors: Discovery, Biology and Clinical Observations
Current Topics in Medicinal Chemistry Sorafenib (BAY 43-9006) in Hepatocellular Carcinoma Patients: From Discovery to Clinical Development
Current Medicinal Chemistry Doxorubicin-Loaded Nanoparticles: New Advances in Breast Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry